Larson Perry W 4
4 · MTS MEDICATION TECHNOLOGIES, INC /DE/ · Filed Dec 22, 2009
Insider Transaction Report
Form 4
Larson Perry W
VP Sales & Marketing
Transactions
- Disposition to Issuer
Options (right to buy)
2009-12-22−10,000→ 0 totalExercise: $13.70Exp: 2017-11-09→ Common Stock (10,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−30,000→ 0 totalExercise: $6.50From: 2004-10-22Exp: 2014-10-22→ Common Stock (30,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−12,821→ 0 totalExercise: $5.85Exp: 2018-07-02→ Common Stock (12,821 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−10,000→ 0 totalExercise: $6.00From: 2006-03-31Exp: 2016-03-31→ Common Stcok (10,000 underlying) - Disposition to Issuer
Options (right to buy)
2009-12-22−11,000→ 0 totalExercise: $6.55From: 2005-02-24Exp: 2015-02-24→ Common Stock (11,000 underlying)
Footnotes (3)
- [F1]The options were cancelled and terminated by the Issuer's Board of Directors in accordance with an Agreement and Plan of Merger, dated as of August 7, 2009 ("Merger Agreement"), by and among the Issuer, MedPak Holdings, Inc., a Delaware corporation ("Parent"), and MedPak Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), whereby Merger Sub merged with and into the Issuer (the "Merger"). The Merger was approved by the stockholders of the Issuer of December 18, 2009 and became effective on December 22, 2009. The reporting person received, with respect to any shares of the Issuer's common stock issuable under a stock option, an amount equal to the excess, if any, of (i) $5.75 per share over (ii) the exercise price per share payable with respect of such shares of the Issuer's common stock issuable under such stock option.
- [F2]Options vested as follows: 3,333 on 11/09/2008; 3,333 on 11/09/2009; and 3,334 on 11/09/2010.
- [F3]Options vested as follows: 4,273 on 7/2/2009; 4,274 on 7/2/2010; and 4,274 on 7/2/2011.